Global Pain Therapeutics Market 2020-2019: Unfulfilled Needs for Analgesics are Identified and Strategies are Outlined to Develop Markets – Stocks News Feed

Wednesday, 11 November 2020, 19:15:00
DUBLIN, Nov. 11, 2020 /PRNewswire/ — The “Pain Therapeutics – Drugs, Markets and Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. The worldwide analgesic markets were analyzed for the year 2019 and projected to 2029. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and… Read More »Global Pain Therapeutics Market 2020-2019: Unfulfilled Needs for Analgesics are Identified and Strategies are Outlined to Develop Markets
— Stocks News Feed

The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings

Sunday, 1 November 2020, 15:40:39
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.
— Benzinga

The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street

Thursday, 8 October 2020, 13:52:19
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) InVitae Corp (NYSE: NVTA ) Insulet Corporation (NASDAQ: PODD ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) (preannounced positive Q3 revenues) Oncorus Inc (NASDAQ: ONCR ) (debuted on Friday) Prelude Therapeutics Inc (NASDAQ: PRLD ) Pulmonx Corp (NASDAQ: LUNG ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) Stoke Therapeutics Inc (NASDAQ: STOK ) (announced decision to dose STK-001 in children and adolescents in its Phase 1/2a study for Dravet syndrome) Surface Oncology Inc (NASDAQ: SURF ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx …
— Benzinga

Monday's Top After-Hours Movers

Tuesday, 22 September 2020, 08:30:13
Gainers Cassava Sciences Inc (NASDAQ: SAVA ) jumped … Full story available on Benzinga.com
— Benzinga

Cassava Sciences Rips Higher After Alzheimer's Drug Meets Study Goals

Monday, 14 September 2020, 18:03:44
Cassava Sciences Inc (NASDAQ: SAVA ) shares were nearly doubling in value Monday following the release of a clinical trial readout. What Happened: Austin, Texas-based Cassava announced final results of a Phase 2b study of its lead drug candidate sumifilam, which showed Alzheimer's patients treated with 50mg or 100mg of sumifilam twice daily for 28 days showed statistically significant improvements in biomarkers of disease pathology, neurodegeneration and neuroinflammation versus a placebo. “The ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease,” according to Cassava Sciences. Sumifilam is a new class of drug that binds to a protein … Full story available on Benzinga.com
— Benzinga